The Minneapolis-based company is developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm.
The Wayne, PA-based company is picking up Essential Medical to help bolster its presence in the structural heart market.
The Burlington, MA-based company said it has acquired the vascular clot management business of Applied Medical Resources for $14.2 million.
During TCT, the Marlborough, MA-based company revealed results of the IMPERIAL study, which showed its Eluvia stent performed significantly better than Cook Medical’s Zilver PTX.
With TCT in full swing, Or Yehuda, Israel-based Cardiovalve is launching the AHEAD US Multicenter Study, and jumping head first into the quickly growing TMVR market.
LivaNova is launching a pivotal study that will look at how stimulation of the vagus nerve with the VITARIA device can help treat heart failure patients.
Medtronic also received FDA approval for revised TAVR labeling that marks a critical moment for treating patients with bicuspid severe aortic stenosis.
The Cupertino, CA-based company garnered a lot of attention for incorporating an ECG into the next iteration of the Apple Watch and now analysts along with industry experts are sounding off on the technology’s potential impact.
Lake Oswego, OR-based Biotronik faces fierce competition from Medtronic, Boston Scientific, and Abbott in the cardiology space, but said its unique technology gives it an advantage.
As renal denervation procedures are making a comeback in treating resistant hypertension, Vascular Dynamics is going a different route to tackle the condition, by developing a stent-like application that will give therapy to patients.
With all of the indications Avinger is pursuing, it seems as if the Redwood City, CA-based company has an ‘infinite’ number of approaches in treating peripheral arterial disease patients.